Drug reference
evolocumab
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Drug class
Cardiovascular (Anti Hyperlipidemics)
Mechanism of action
Monoclonal antibody that binds to PCSK9 (proprotein convertase subtilisin/kexin type 9), LDL-C is cleared from the circulation preferentially through the LDL receptor (LDLR) pathway, PCSK9 is a serine protease that destroys LDLR in the liver, resulting in decreased LDL-C clearance and increased plasma LDL-C
Common side effects
- Nasopharyngitis
- Back pain
- Influenza
Related conditions
Frequently asked questions
What drug class is evolocumab?
evolocumab belongs to: Cardiovascular.
How does evolocumab work?
Monoclonal antibody that binds to PCSK9 (proprotein convertase subtilisin/kexin type 9), LDL-C is cleared from the circulation preferentially through the LDL receptor (LDLR) pathway, PCSK9 is a serine protease that destroys LDLR in the liver, resulting in decreased LDL-C clearance and increased plasma LDL-C
What are the common side effects of evolocumab?
Nasopharyngitis, Back pain, Influenza
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.